GT Biopharma Advances AML/MDS and Solid Tumor Phase 1 Trials with $13M Valuation
GTBP•GT Biopharma has a $13 million market cap and three TriKE immuno-oncology drugs in Phase 1 trials, including GTB-3650 AML/MDS dose-escalation with eight patients across four cohorts and no dose-limiting toxicities. In May 2026, it dosed the first patient in a Phase 1 GTB-5550 B7-H3 solid-tumor trial using subcutaneous injections.
1. Company Market Cap and TriKE Platform
GT Biopharma trades at a market capitalization near $13 million and holds exclusive worldwide rights to the Tri-specific Killer Engager (TriKE) platform licensed from the University of Minnesota. The TriKE molecules are engineered to bind CD16 on NK cells, a cancer cell antigen, and IL-15 to activate and expand NK cells.
2. GTB-3650 Phase 1 AML/MDS Trial
The lead candidate, GTB-3650, is in a Phase 1 dose-escalation trial for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. As of Q1 2026, eight patients have been treated across four cohorts without dose-limiting toxicities, and the study may escalate to seven cohorts with a key data update expected in H2 2026.
3. GTB-5550 Phase 1 Solid-Tumor Trial
In May 2026, GT Biopharma dosed the first patient in the Phase 1 trial of GTB-5550, targeting the B7-H3 antigen on solid tumors. The trial begins with dose escalation in metastatic castration-resistant prostate cancer and will expand into a multi-tumor basket across up to seven solid tumor types, using subcutaneous injections.
4. Market Opportunity and Next Steps
The global oncology market is projected to grow from $139 billion in 2025 to $268 billion by 2034, with solid tumors representing a substantial segment. GT Biopharma plans to leverage its TriKE platform across diverse indications, aiming for interim data readouts and potential partnerships to support further clinical development.
